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San-Huang-Xie-Xin-Tang (SHXT), composed of Coptidis rhizoma, Scutellariae radix and Rhei rhizoma, is a traditional Chinese
herbal medicine used to treat gastritis, gastric bleeding and peptic ulcers. This study investigated the neuroprotective eﬀects of
SHXT on microglia-mediated neurotoxicity using co-cultured lipopolysaccharide (LPS)-activated microglia-like BV-2 cells with
neuroblastoma SH-SY5Y cells. Eﬀects of SHXT on 6-hydroxydopamine (6-OHDA)-induced neurotoxicity were also examined in
SH-SY5Y cells. Results indicated SHXT inhibited LPS-induced inﬂammation of BV-2 cells by downregulation of iNOS, NO, COX-
2, PGE2, gp91phox, iROS, TNF-α,I L - 1 β, inhibition of IκBα degradation and upregulation of HO-1. In addition, SHXT increased
cell viability and down regulated nNOS, COX-2 and gp91phox of SH-SY5Y cells co-cultured with LPS activated BV-2 cells. SHXT
treatment increased cell viability and mitochondria membrane potential (MMP), decreased expression of nNOS, COX-2, gp91phox
and iROS, and inhibited IκBα degradation in 6-OHDA-treated SH-SY5Y cells. SHXT also attenuated LPS activated BV-2 cells- and
6-OHDA-induced cell death in diﬀerentiated SH-SY5Y cells with db-cAMP. Furthermore, SHXT-inhibited nuclear translocation
of p65 subunit of NF-κB in LPS treated BV-2 cells and 6-OHDA treated SH-SY5Y cells. In conclusion, SHXT showed protection
from activated microglia- and 6-OHDA-induced neurotoxicity by attenuating inﬂammation and oxidative stress.
1.Introduction
Inﬂammation appears to be a complicating factor in many
age-related neurodegenerative diseases, such as Parkinson’s
disease (PD) [1], Alzheimer’s disease (AD) [2]a n dm u l -
tiple sclerosis [3]. Microglia are thought to mediate the
innate defense system in the central nervous system [4].
Activated microglia enhances pro-inﬂammatory and neu-
rotoxic responses and neuronal injury [5, 6]. Microglia-
mediated neurotoxicity was induced through release of pro-
inﬂammatory cytokines such as tumor-necrosis factor alpha
(TNF)-α, interleukin 1β (IL-1β), nitric oxide (NO) and
prostaglandin E2 (PGE2), this yields enhanced reactive oxy-
gen species (ROS) [7] and reactive nitric oxide species (RNS)
[8, 9]. The deleterious consequences of excessive oxidation
and pathophysiological role of ROS have been intensively
studied in Alzheimer’s disease. Studies indicated that anti-
inﬂammatory or anti-oxidative stress drugs exert neuropro-
tective eﬀects [10–13]. Therefore, anti-inﬂammatory agents
and antioxidants are considered a promising approach to
slowing the progression and limiting the extent of neuronal
cell loss in these disorders.
Many herbal medicines and dietary supplements are sold
as aids to improve memory, treat neurodegenerative diseases
or create favorable eﬀects on the central nervous system.
Increasing evidence has suggested that traditional Chinese
medicines or herbal extracts possess neuroprotective beneﬁts
through their distinct and multiple mechanisms, including
anti-inﬂammation and anti-oxidation [14–19]. San-Huang-
Xie-Xin-Tang (SHXT), a traditional Chinese medicinal for-
mula containing Coptidis rhizome (Coptis chinesis Franch),
Scutellariae radix (Scutellaria baicalensis Georgi) and Rhei
rhizome (Rheum oﬃcinale Baill), has been used to treat
gastritis, gastric bleeding and peptic ulcers [20]. The preven-
tive eﬀects of SHXT on lipopolysaccharide (LPS) and Heli-
cobacter pylori-induced inﬂammatory responses have been
conﬁrmed by our previous studies [21–23]. Studies indicate
that several components in SHXT show inhibitory eﬀects on2 Evidence-Based Complementary and Alternative Medicine
neurotoxicity. Baicalein and baicalin, the major ﬂavonoids
in Scutellaria baicalensis, can reduce beta amyloid protein-
induced neurotoxicity [24]. Baicalein [14, 18] and wogonin
[19] attenuate inﬂammation-mediated neurodegeneration
[14, 18, 19]. Baicalin attenuates oxygen-glucose deprivation-
induced injury in neurons [25]. Emodin, an anthraquinone
derivative extracted from Rhei rhizome, decreases glutamate-
induced neurotoxicity [26].
LPS is commonly used to investigate the impact of
inﬂammation on neuronal death, and studies indicate that
microglia are necessary for LPS-induced neurotoxicity [27,
28]. LPS is not toxic to neurons, but LPS stimulates glial
cells to produce factors that are toxic to neurons [28–30]. On
the other hand, the auto-oxidation of the neurotransmitter
dopamine to 6-hydroxydopamine (6-OHDA) generates ROS
and reactive quinones subsequently inducing cell death [31,
32]. Therefore, we investigated the eﬀects of SHXT on LPS
activated microglia-induced neurotoxicity by using the in
vitro model of co-culture microglia-like BV-2 cells with the
neuronal-like neuroblastoma SH-SY5Y cell. We also exam-
ined the eﬀects of SHXT on 6-OHDA-induced neurotoxicity
in dopaminergic neuroblastoma SH-SY5Y cells.
2.MaterialsandMethods
2.1. Reagents. The voucher specimen and method for
extraction and analysis of SHXT were described previously
[22]. Brieﬂy, a blended mixture of Coptidis rhizome,r o o to f
Scutellariae radix and rhizome of Rhei oﬃcinale Baill was
prepared in a ratio of 1:1:2, respectively. The content of
each component in SHXT is shown as follows (μg/mL):
baicalin 1153.07±56.36, baicalein 82.81±3.74, emodin
11.15±1.22, wogonin 19.55±0.83, rhein 126.12±3.84,
berberine 62.14±4.27, coptisine 6.15±0.34, palmatine
25.11±3.78, sennoside A 128.02±13.56 and sennoside
B 95.90±3.59. Dimethyl sulfoxide (DMSO), lipopolysac-
charide (LPS, L8274) from Escherichia coli (O26:B6), 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromi-
de (MTT), 2 ,7 -dichloro-dihydroﬂuorescein diacetate
(H2DCF-DA), 6-hydroxydopamine (6-OHDA), dibutyryl
cyclic AMP (db-cAMP), mouse antibody against iNOS
and β-actin were purchased from Sigma Aldrich (USA).
Dulbecco’s modiﬁed Eagle’s medium (DMEM), fetal bovine
serum (FBS), penicillin, amphotericin B and streptomycin
were purchased from GIBCO/BRL Life Technologies (USA).
Mouse antibody against gp91phox and all materials for
SDS-polyacrylamide gel electrophoresis were purchased
from Bio-Rad (USA). Goat antibody against COX-2 and
HO-1, mouse antibody against IκBα, rabbit antibody against
nNOS and all horseradish peroxidase-conjugated secondary
antibodies were purchased from Santa Cruz Biotechnology
(USA). Enhanced chemiluminescence agent was purchased
from PerkinElmer Life and Analytical Sciences (USA).
TNF-α,I L - 1 β and PGE2 enzyme immunoassay kits and
NE-PER Nuclear and Cytoplasmic Extraction Reagents were
purchased from Pierce Endogen (USA). TransFactor Family
Colorimetric Kit NF-κB was purchased from BD Bioscience,
Clontech (USA). All other chemicals were purchased from
Sigma Chemical Company (USA).
2.2. Microglial BV-2 Cell Culture and Activated Microglia
with LPS. Mouse microglial cell line BV-2 was cultured in
DMEM containing 10% (v/v) heat-inactivated FBS, 4mM
glutamine, 100U/mL penicillin, 100mg/mL streptomycin
and 0.25mg/mL amphotericin B at 37◦C in a humidiﬁed
incubator under 5% CO2 and 95% air. For the purpose of
experiment,BV-2cellswereplatedin6-,24-or96-wellsterile
plates (1×105 cells/mL). Then, cells were stimulated with
LPS alone (100ng/mL) or LPS with diﬀerent concentrations
of SHXT.
2.3. Human SH-SY5Y Neuroblastoma Cell Culture. The
human neuroblastoma cell line SH-SY5Y (ATCC CRL-2266)
was cultured in a medium consisting of a 1:1 mixture
of DMEM and Ham’s F-12 medium containing 10% heat-
inactivated FBS, 4mM glutamine, 100U/mL penicillin,
100mg/mL streptomycin and 0.25mg/mL amphotericin B
at 37◦C in a humidiﬁed incubator under 5% CO2 and
95% air. In order to investigate the neuroprotective eﬀect
of SHXT on diﬀerentiated neuronal cell, SH-SY5Y cells
were treated with 1mM db-cAMP, a permeable analog of
cAMP, to induce neuronal diﬀerentiation. SH-SY5Y cells
(1×105 cells/mL) were plated in 96-well sterile plates and
db-cAMP was dissolved in distilled water and added to each
well at a concentration of 1mM in DMEM containing 10%
FBS. The cells were then incubated for 4 days at 37◦C,
with the medium refreshed daily. Then, cells were treated
with 6-OHDA alone (100μM) or 6-OHDA with diﬀerent
concentrations of SHXT for 24h.
2.4. Co-Culture of SH-SY5Y Cells with Microglial BV-2
Cells. The eﬀects of SHXT on microglia-mediated and
inﬂammation-associated neuronal damage were determined
using LPS stimulated BV-2 cells as a model of acti-
vated microglia [11]. Non-diﬀerentiated or diﬀerenti-
ated SH-SY5Y cells were plated in 6- or 24-well plates
(1×105 cells/mL) and BV-2 cells were seeded onto cell
culture inserts (pore size of 0.2μm; NUNCA/S, Roskilde,
Denmark). Then the inserts were placed in the wells where
SH-SY5YcellsweregrowinginDMEMcontaining10%(v/v)
heat-inactivated FBS, 4mM glutamine, 100U/mL penicillin,
100mg/mL streptomycin and 0.25mg/mL amphotericin B
at 37◦C in a humidiﬁed incubator under 5% CO2 and 95%
air. The BV-2 and SH-SY5Y co-cultured cells were separated
by ﬁlters present in the insert. In co-culture conditions,
BV-2 cells were then stimulated with LPS (100ng/mL) or
LPS+SHXT for 24h.
2.5. Cell Viability Assay. Cell viability was measured by a
quantitative colorimetric assay with MTT, showing mito-
chondrial activity of living cells. In mono-culture, BV-2
or SH-SY5Y cells in 96-well plates were incubated with
25–200μg/mL of SHXT for 24h. In 6-OHDA-induced
neurotoxicity, non-diﬀerentiated or diﬀerentiated SH-SY5Y
cells were treated with or without 6-OHDA (100μM) or 6-
OHDA+SHXT for 24h. Under co-culture conditions, BV-
2 cells were treated with or without LPS (100ng/mL) or
LPS+SHXT for 24h. After incubation, inserts containingEvidence-Based Complementary and Alternative Medicine 3
BV-2cellswereremoved.Non-diﬀerentiatedordiﬀerentiated
SH-SY5Y cells were incubated with MTT at a ﬁnal con-
centration of 0.5mg/mL for 3h at 37◦C. The reaction was
terminated by addition of 200μLo fD M S O .T h ea m o u n to f
MTT formazon product was then determined by measuring
the absorbance at 560nm using a microplate reader.
2.6. Nitrite Measurement. Production of nitric oxide (NO)
was determined by measuring the level of accumulated
nitrite, a metabolite of NO in the culture supernatant
using Griess reagent (1% sulfanilamide and 0.1% N-(1-
naphthyl)ethylenediamide in 5% phosphoric acid). After
24h of treatment with LPS (100ng/mL) alone or LPS +
SHXT, the culture supernatants were collected and mixed
with an equal volume of Griess reagent and incubated at
roomtemperaturefor10min.Theabsorbancewasmeasured
at 540nm (OD540).
2.7.Enzyme-Linked Immunosorbent Assay(ELISA). Thepro-
ductions of IL-1β,P G E 2 and TNF-α in supernatant were
detected using ELISA kits from Endogen (USA) according
to the manufacturer’s instructions. IL-1β and PGE2 in the
supernatant were determined after 24h of LPS treatment.
TNF-α was determined after 2h of LPS treatment.
2.8. NF-κB DNA-Binding Activity. The DNA-binding activ-
ities of transcription factors in cells were determined by
enzyme-linked DNA-protein interaction assay (ELDIA),
accordingtoapreviouslydescribedmethod[21,33].Nuclear
protein extracts were prepared using NE-PER Nuclear and
Cytoplasmic Extraction Reagent as described previously
[34]. DNA-p65 NF-κB-binding activity was measured with
a BD Mercury TransFactor kit (BD Bioscience, Clontech),
which detects DNA binding by speciﬁc transcription factors,
according to the manufacturer’s instructions [35].
2.9. Western Blot Analysis. After treatment with indicated
agents, cells were collected and lysed to determine expression
of nNOS, iNOS, COX-2, gp91phox,I κBα and HO-1. The
lysates were centrifuged at 15000×gf o r3 0m i na t4 ◦C. The
supernatant was then collected for SDS-polyacrylamide gel
electrophoresis. Protein concentration was determined with
the Bio-Rad protein assay kit following the manufacturer’s
guide. Cell membranes were obtained by ultracentrifugation
of the supernatant at 26000×gf o r1 ha t4 ◦C. Equal
amounts of protein (20μg per lane) were separated on a
10% polyacrylamide gel and transferred to polyvinylidene
diﬂuoride membranes (PerkinElmer Life and Analytical
Sciences). Non-speciﬁc binding was blocked with TBST
(50mM Tris- HCl, pH 7.6, 150mM NaCl, 0.1% Tween 20)
containing5%non-fatmilkfor1hatroomtemperature.The
membranes were then each incubated overnight at 4◦Cw i t h
oneofthefollowingspeciﬁcprimaryantibodies:mouseanti-
iNOS (1:1000), mouse anti-gp91phox (1:1000), mouse anti-
β-actin (1:20000), rabbit anti-nNOS (1:1000), mouse anti-
IκBα (1:500), rabbit anti-HO-1 (1:1000) and goat anti-
COX-2 (1:5000). Membranes were washed six times for
5min with TBST. The appropriate dilutions of secondary
antibodies (diluted 1:1000) were incubated for 1h. After six
washes with TBST, the protein bands were detected with the
enhanced chemiluminescence reagent (PerkinElmer Life and
Analytical Sciences).
2.10. Measurement of Intracellular Reactive Oxygen Species.
The level of intracellular reactive oxygen species (ROS)
was quantiﬁed by ﬂuorescence with H2DCF-DA. Following
incubations with the indicated treatments, microglial BV-2
cells or neuronal SH-SY5Y cells were loaded with 10μMo f
H2DCF-DAfor30minat37◦C. Cells were then washed three
times with phosphate-buﬀer saline, pH 7.4, and the relative
levels of ﬂuorescence were analyzed by a spectrophotoﬂu-
orimeter (FLUOstar OPTIMA, BMG LABTECH, Germany,
495nm excitation and 520nm emission). Intracellular ROS-
containing cells were identiﬁed as those with increased FITC
ﬂuorescence of oxidized H2DCF.
2.11. Measurement of Mitochondrial Membrane Potential.
Mitochondrial membrane potential was measured by the
incorporation of a cationic ﬂuorescent dye rhodamine 123.
The reduction in ﬂuorescent intensity of rhodamine 123
staining represented a fall in the mitochondrial membrane
potential. After 24h of incubation in normal medium with
or without treatment, the cells were changed to serum-
free medium containing 10μM rhodamine 123, there they
were incubated for 15min at 37◦C. The cells were then
collected, and the ﬂuorescence intensity was analyzed within
15min by a spectrophotoﬂuorimeter (FLUOstar OPTIMA,
BMG LABTECH, Germany, 490nm excitation and 515nm
emission).
2.12. Data Analysis. Data were expressed as mean±SEM.
Analysis of variance (ANOVA) was used to assess the statis-
tical signiﬁcance of the diﬀerences followed by Tukey’s test
for all pair’s comparisons. A value of P< .05 was considered
statistically signiﬁcant. The data were analyzed with the
Statistical Package for Social Sciences (SPSS, Chicago, IL).
3. Results
3.1. Eﬀects of SHXT on LPS-Activated Microglial BV-2 Cell-
a n d6 - O H D A - I n d u c e dL o s so fS H - S Y 5 YC e l lV i a b i l i t y .Cells
were incubated with or without SHXT for 24h. According to
the results of MTT assay, SHXT (25, 50, 100 and 200μg/mL)
did not eﬀect the cell viability of BV-2 cells (Figure 1(a))a n d
SH-SY5Y cells (Figure 1(b)). In order to examine the eﬀect
of SHXT on LPS-activated microglia-mediated cell viability,
co-culture of BV-2 cells with non-diﬀerentiated or diﬀeren-
tiated SH-SY5Y cells was investigated. As shown in Figures
1(c) and 1(d), SHXT attenuated LPS (100ng/mL)-activated
BV-2 cells-induced cell death in non-diﬀerentiated and
diﬀerentiated SH-SY5Y cells. Moreover, exposure of non-
diﬀerentiated (Figure 1(e)) and diﬀerentiated (Figure 1(f))
SH-SY5Y cells to 6-OHDA induced signiﬁcant cell death.
SHXT increased cell viability in 6-OHDA treated non-
diﬀerentiated (Figure 1(e)) and diﬀerentiated (Figure 1(f))
SH-SY5Y cells. SHXT protected against activated microglia-
and 6-OHDA-induced diﬀerentiated neuronal cell death4 Evidence-Based Complementary and Alternative Medicine
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Figure 1:EﬀectsofSHXTonmicroglialBV-2cells(a),neuroblastomaSH-SY5Ycells(b),lipopolysaccharide(LPS,100ng/mL)activatedBV-
2treatednon-diﬀerentiated(c)anddiﬀerentiated(d)SH-SY5Ycells,and6-hydroxydopamine(6-OHDA,100μM)treatednon-diﬀerentiated
(e) and diﬀerentiated (f) SH-SY5Y cells. Cells were treated with SHXT (25–200μg/mL) for 24h. Cell viability was determined by MTT assay.
Bars represent the mean ± SEM from six independent experiments. #P< .05 versus control, ∗P< .05 versus LPS or 6-OHDA only.
at the concentrations from 100 to 200μg/mL and 50 to
200μg/mL, respectively. In addition, we examined dopamine
receptor expression of diﬀerentiated SH-SY5Y cells using
western blotting, and marked increase of dopamine receptor
expression was observed (online Supplementary Figure S1).
3.2. LPS-Induced Inﬂammation and Associated Oxidative
Stress-Related Factors in BV-2 Cells were Reduced by SHXT.
To investigate whether SHXT inhibited LPS-activated
microglia-inducedinﬂammatoryandoxidativestressfactors,
the eﬀects of SHXT on the associated noxious factors
of LPS-treated BV-2 cells were examined. As shown in
Figure 2, LPS (100ng/mL) increased expression of iNOS,
COX-2 and gp91phox in BV-2 cells, which were inhibited
by SHXT treatment. Pairwise comparison at each concen-
tration by Tukey’s test indicated that SHXT concentration-
dependently inhibited iNOS at a concentration of 50 and
200μg/mL and inhibited COX-2at a concentration of 25, 50,
100 and 200μg/mL. Additionally, SHXT upregulated HO-
1 expression in LPS treated BV-2 cells in a concentration-
dependent manner from 25 to 200μg/mL (Figure 2(d)).
SHXT also reduced LPS-induced NO, PGE2 and iROSEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of SHXT on expression of iNOS, COX-2, gp91phox and HO-1 in BV-2 cells treated with lipopolysaccharide (LPS,
100ng/mL) for 24h. Cultures were pretreated with SHXT for 30min before the addition of LPS treatment. Bars represent the mean±SEM
from six independent experiments. Densitometry analyses are presented as the relative ratio of protein/β-actin protein, and are represented
as percentages of the control group. #P< .05 versus control, ∗P< .05 versus LPS only.
Table 1: Eﬀects of SHXT (25, 50, 100 and 200μg/mL) on LPS-induced nitrite, PGE2, iROS, TNF-α and IL-1β production in BV-2 cells.
Nitrite (μM) PGE2 (pg/mL) iROS (%) TNF-α (pg/mL) IL-1β (pg/mL)
Control 0.25 ± 0.03 14.45 ± 1.53 100 70.41 ±8. 51 10.51 ± 3.57
LPS only 3.76 ± 0.20# 41.83 ± 2.53# 201.52 ± 9.52# 704.61 ± 30.53# 68.51 ± 5.65#
LPS + SHXT 25μg/mL 2.96 ± 0.41 27.39 ± 2.14∗ 192.51 ± 8.52 650.25 ± 20.56 58.52 ± 7.24
LPS + SHXT 50μg/mL 1.89 ± 0.34∗ 22.52 ± 1.95∗ 182.57 ± 8.50 552.53 ± 10.51∗ 50.14 ± 4.65∗
LPS + SHXT 100μg/mL 1.63 ± 0.21∗ 21.62 ± 1.52∗ 130.73 ± 6.25∗ 430.56 ± 12.86∗ 42.51 ± 4.64∗
LPS + SHXT 200μg/mL 1.50 ± 0.14∗ 14.68 ± 1.35∗ 109.64 ± 6.63∗ 263.50 ± 15.58∗ 26.52 ± 5.63∗
Values represent the mean ± SEM from six independent experiments. #P< .05 versus control, ∗P< .05 versus LPS only.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of SHXT on the IκBα expression (a) and NF-κB
activation (b) in lipopolysaccharide (LPS, 100ng/mL)-treated BV-
2 cells. Cultures were pretreated with SHXT for 30min before the
addition of LPS. Then the cells were collected at 1h for NF-κB
activity assay and at 24h for IκBα protein analyses. Densitometry
analyses are presented as the relative ratio of protein/β-actin
protein, and they are represented as percentages of the control
group. Changes of NF-κBp65 translocation levels are represented
as percentages of the control group. Bars represent the mean±SEM
fromsixindependentexperiments. #P< .05versuscontrol, ∗P< .05
versus LPS only.
production (Table 1). Furthermore, SHXT (50–200μg/mL)
concentration-dependentlyattenuatedIκBαdegradationand
NF-κBp65translocationinLPS-treatedBV-2cells(Figure 3).
3.3. SHXT Inhibited Overproduction of TNF-α and IL-1β in
LPS-Treated BV-2 Cells and Overexpression of nNOS, COX-
2a n dg p 9 1 phox in SH-SY5Y Cells Co-Cultured with BV-
2C e l l s .As shown in Table 1, LPS (100ng/mL) caused a
marked increase of TNF-α at 2h and IL-1β at 24h in BV-
2 cells. Results indicated SHXT concentration-dependently
attenuated LPS-induced overproduction of TNF-α and IL-
1β from 25 to 200μg/mL and 50 to 200μg/mL, respectively.
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Figure 4: Inhibitory eﬀects of SHXT on the expressions of nNOS
(a), COX-2 (b) and gp91phox (c) in SH-SY5Y cells under co-
culture with lipopolysaccharide (LPS, 100ng/mL)-treated BV-2
cells. Cultures were pretreated with SHXT for 30min followed by
LPS treatment for 24h. Densitometry analyses are presented as
the relative ratio of protein/β-actin protein, and are represented as
percentages of the control group. Bars represent the mean±SEM
fromsixindependentexperiments. #P< .05versuscontrol, ∗P< .05
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Figure 5: Inhibitory eﬀects of SHXT on the expressions of nNOS (a), COX-2 (b), IκBα(c) and NF-κB activation (d) on 6-hydroxydopamine
(6-OHDA, 100μM) treated SH-SY5Y cells. Cultures were pretreated with SHXT for 30min before the addition of 6-OHDA. Then the cells
were collected at 1.5h for NF-κB activity assay and at 24h for nNOS, COX-2 and IκBα protein analyses. Densitometry analyses are presented
as the relative ratio of protein/β-actin protein, and are represented as percentages of the control group. Changes of NF-κB p65 translocation
levels are represented as percentages of the control group. Bars represent the mean±SEM from six independent experiments. #P< .05 versus
control, ∗P< .05 versus 6-OHDA only.
Under co-culture conditions, LPS exposure induced upreg-
ulation of nNOS, COX-2 and gp91phox of SH-SY5Y cells.
However,SHXT(50–200μg/mL)concentration-dependently
attenuated LPS-activated BV-2 cell-induced overexpression
of nNOS (Figure 4(a)), COX-2 (Figure 4(b))a n dg p 9 1 phox
(Figure 4(c)) on SH-SY5Y cells.
3.4. 6-OHDA-Induced Inﬂammatory Factors and Mitochondr-
ial Membrane Potential Changes in SH-SY5Y Cells Were
Attenuated by SHXT. SH-SY5Y cells treated with 6-OHDA
(100μM) for 24h resulted in signiﬁcant increases in
expression of nNOS (Figure 5(a)) and COX-2 (Figure 5(b)),
which were inhibited by SHXT (25–200μg/mL). SHXT
also inhibited 6-OHDA-induced IκBα degradation
(Figure 5(c))a n dN F - κBp65 translocation (Figure 5(d))
at a concentration of 100μg/mL and 200μg/mL. SHXT
(25–200μg/mL) attenuated 6-OHDA-induced increases of
gp91phox (Figure 6(a)) and iROS(Figure 6(b)).Furthermore,
SHXT (50–200μg/mL) signiﬁcantly attenuated 6-OHDA-
induced decrease in mitochondria membrane potential
(Figure 6(c)).8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Eﬀects of SHXT on 6-hydroxydopamine (6-OHDA,
100μM)-induced changes of gp91phox expression (a), iROS forma-
tion (b) and mitochondria membrane potential (c) in SH-SY5Y
cells. The iROS was measured by using H2DCF-DA staining and
mitochondrial membrane potential was measured by rhodamine
123. Densitometry analyses are presented as the relative ratio
of protein/β-actin protein, and are represented as percentages
of the control group. Bars represent the mean±SEM from six
independent experiments. #P< .05 versus control group, ∗P< .05
versus 6-OHDA only.
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Figure 7: Hypothetical protective mechanisms of SHXT on
microglia-mediated and 6-OHDA-induced toxicity in neuronal
cells.
4. Discussion
The present study demonstrated that SHXT could inhibit
LPS-activated microglia- and neurotoxin 6-OHDA-induced
neurotoxicity. The major ﬁndings showed that SHXT sig-
niﬁcantly reduced LPS-activated microglia- and 6-OHDA-
induced neuronal cell death. In LPS-activated microglia-
like BV-2 cells, SHXT attenuated inﬂammatory cytokine
TNF-α and IL-1β, decreased the production of NO, PGE2
and iROS, downregulated overexpression of iNOS, COX-
2a n dg p 9 1 phox, decreased IκBα degradation and NF-
κBp65 translocation, and upregulated HO-1 expression.
Moreover, SHXT downregulated overexpression of nNOS,
COX-2, gp91phox on neuronal SH-SY5Y cells co-cultured
with activated microglia BV-2 cells. In 6-OHDA-induced
neurotoxicity, the protective eﬀects of SHXT are mediated
by downregulating nNOS, COX-2 and gp91phox, decreased
iROS level, IκBα degradation and NF-κBp65 translocation
and increased mitochondria membrane potential of SH-
SY5Y cells (Figure 7).
Microglial-mediated neurotoxicity has been implicated
in numerous neurodegenerative diseases [29]. Activated
microglia increase oxidative stress [36] and inﬂammatory
mediators [37]. Pro-inﬂammatory cytokines TNF-α and IL-
1β are thought to play a major role in inducing neuronal
death [38]. In this study, SHXT signiﬁcantly attenuated LPS-
inducedincreaseofpro-inﬂammatorycytokines(TNF-αand
IL-1β) on BV-2 cells. Moreover, pro-inﬂammatory cytokines
can induce iNOS expression and subsequently induce large
amounts of NO production in activated microglia [7]. NO,
together with iNOS and nNOS, is known to be involved
in the pathogenesis of PD [39, 40]. Excessive accumulation
of NO has long been known to be toxic to neurons [41].
O x y g e nf r e era d i c a l ss u c ha ss u pe r o x i d ec a nr e a ctwi t hN Ot o
form much more deadly intermediates such as peroxynitrite
[42]. The current results indicated that SHXT not only
reduced LPS-activated microglia-induced increase of iNOS
and NO, but also decreased the overexpression of nNOS
in microglia-stimulated neuronal SH-SY5Y cells. SHXT alsoEvidence-Based Complementary and Alternative Medicine 9
attenuated the overexpression of nNOS induced by 6-OHDA
in SH-SY5Y cells. COX-2 is believed to be a critical enzyme
in the inﬂammatory response and has been implicated in
neuronal survival and death [43]. Cytokines (particularly
TNF-α) activate COX-2 enzymes, and inhibition of COX-2
has been shown to provide neuroprotection [44]. Our results
showed that SHXT not only decreased TNF-α production
but also attenuated COX-2 expression and PGE2 production
on LPS-treated microglia BV-2 cells. SHXT also inhibited
overexpression of COX-2 on activated microglia-treated or
6-OHDA-treated neuronal SH-SY5Y cells. It is well known
that HO-1 can inhibit iNOS expression and NO production
in activated macrophages via inactivation of NF-κB[ 45, 46].
Our results showed that SHXT inhibited LPS-induced iNOS
e x p r e s s i o n ,N Op r o d u c t i o n ,I κBα degradation and NF-κB
p65 translocation. SHXT also enhanced HO-1 expression.
Phagocyte NADPH oxidase (PHOX) is a major source
of superoxide and the catalytic center of this oxidase is the
membrane-integrated protein gp91phox [47, 48]. NADPH
oxidase is deeply involved with microglia-induced neuro-
toxicity as a result of either generating extracellular ROS or
by increasing microglia intracellular ROS production, which
activates the generation of pro-inﬂammatory mediators and
subsequently induces damages to neurons [1]. Microglia are
critical to NADPH oxidase-mediated neurotoxicity in LPS-
induced inﬂammation-mediated neurodegeneration [49].
Our study showed that SHXT decreased gp91phox overex-
pression and iROS levels on LPS-activated BV-2 cells. SHXT
also downregulated gp91phox overexpression on SH-SY5Y
cells co-cultured with LPS-activated microglia BV-2 cells.
Additionally,NADPHoxidase-generatedROSareinvolvedin
the signaling event leading to COX-2 expression and PGE2
production in microglia treated with LPS [50]. The present
resultsindicatedSHXTinhibitedgp91phox,iROS,COX-2and
PGE2. Therefore, the protective eﬀects of SHXT on LPS-
activated microglia-induced neuronal cell damage might be
due to its anti-inﬂammatory and anti-oxidative eﬀects.
It has been reported that the auto-oxidation of dopamine
to 6-OHDA generates ROS and reactive quinones [31, 32],
which subsequently induces lipid peroxidation, damages
mitochondrial membrane and results eventually in the
collapse of mitochondrial membrane potential, leading to
cell death [51]. The present results indicated that SHXT
decreased gp91phox overexpression and iROS levels in SH-
SY5Y cells exposed to 6-OHDA. SHXT also attenuated
the decrease of mitochondrial membrane potential and
cell death induced by 6-OHDA. Furthermore, SHXT also
inhibited6-OHDA-inducedincreasesofnNOS,COX-2,IκBα
degradation and NF-κBp65 translocation. Therefore, the
prevention of SHXT on 6-OHDA-induced neuronal cell
damage might be partly mediated via decreasing production
of iROS, increasing mitochondrial membrane potential and
attenuating overexpression of inﬂammatory protein.
In conclusion, this study suggests that SHXT can eﬀec-
tively attenuate LPS-activated microglia- and neurotoxin 6-
OHDA-induced neurotoxicity. Considering the importance
of inﬂammation and ROS in neurodegeneration, SHXT
might have a protective potential in the microglia-mediated
or oxidative stress-related neurodegenerative disorders.
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